A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
A phase 3 trial of Divarasib, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT07541170 by Hoffmann-La Roche, with 400 participants planned, started 2026-09-30 and due to reach its primary completion in 2032-01-31. Interventions recorded: Divarasib, Pembrolizumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par
Shares Divarasib, Roche / Genentech, Pembrolizumab, Small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip
Shares Divarasib, Roche / Genentech, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Shares Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.